Roots Analysis has done a detailed study on Proteome Profiling Services Market, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 290+ page report, which features 50+ figures and 100+ tables, please visit this link
Key Market Insights
- Over 200 players situated across the globe, claim to offer a variety of services for proteome profiling, and have developed the required expertise to process different sample types
- The market is fragmented, featuring the presence of both industry and non-industry players that are involved in providing proteome profiling services for various applications
- The current landscape includes a mix of both established players and new entrants; close to 40% of the companies offering proteome profiling services were established over the last two decades
- Several contract service providers, involved in this domain, are steadily expanding their capabilities in order to enhance their respective proteome profiling service portfolio and maintain a competitive edge in the industry
- The growing trend of outsourcing proteome profiling operations is evident form the rise in recent partnership activity; the maximum number of collaborations were observed to have been inked in 2019
- The benefits of proteome profiling service presently outweigh the challenges related to their existing capabilities; the growing optimism in this domain is evident in the opinions of industry veterans
- The market is anticipated to grow at CAGR of 15%, till 2030, and the projected opportunity is likely to be distributed across various type of applications, sponsors and key geographical regions
For more information, please visit https://www.rootsanalysis.com/reports/proteome-profiling-services.html
Table of Contents
- PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
INTRODUCTION
3.1. Chapter Overview
3.2. Proteome Profiling
3.2.1. Proteome Profiling Process
3.2.1.1. Protein Extraction, Separation and Purification
3.2.1.2. Protein Characterization
3.2.1.3. Protein Sequencing
3.2.1.4. Protein Quantification
3.2.1.5. In silico Analysis
3.2.1.6. Analysis of Post Translational Modifications
3.2.2. Proteome Profiling Technologies
3.2.2.1. Type of Proteome Profiling Technologies
3.2.3. Applications of Proteome Profiling
3.2.3.1. Biomarker Discovery
3.2.3.2. Disease Diagnosis
3.2.3.3. Drug Discovery
3.2.3.4. Elucidation of Cause / Propagation of Diseases
3.2.3.5. Toxicoproteomic Studies
3.2.4. Challenges Associated with Proteome Profiling
3.2.5. Outsourcing of Proteome Profiling
3.2.6. Concluding Remarks
- MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Proteome Profiling Service Providers: Overall Market Landscape
4.2.1. Analysis by Type of Organization
4.3. Industry Players: Overall Market Landscape
4.2.1. Industry Players: Analysis by Year of Establishment
4.2.2. Industry Players: Analysis by Company Size
4.2.3. Industry Players: Analysis by Location of Headquarters
4.2.4. Industry Players: Analysis by Type of Service(s) Offered
4.3.4.1. Industry Players: Analysis by Service(s) Offered for Pre-Proteome Profiling
4.3.4.2. Industry Players: Analysis by Service(s) Offered for Proteome Profiling
4.3.4.3. Industry Players: Analysis by Other Service(s) Offered for Proteome Profiling
4.3.5. Industry Players: Analysis by Company Size and Type of Service(s) Offered
4.3.6. Industry Players: Analysis by Type of Product Profiled
4.2.7. Industry Players: Analysis by Type of Sample(s) Used
4.3.8. Industry Players: Analysis by Number of Sample(s) Used and Company Size
4.3.9. Industry Players: Analysis by Type of Application
4.3.10. Industry Players: Analysis by Company Size and Type of Application
4.4. Non-Industry Players: Overall Market Landscape
4.4.1. Non-Industry Players: Analysis by Year of Establishment
4.4.2. Non-Industry Players: Analysis by Company Size
4.4.3. Non-Industry Players: Analysis by Location of Headquarters
4.4.4. Non-Industry Players: Analysis by Service(s) Offered
4.4.4.1. Non-Industry Players: Analysis by Service(s) Offered for Pre-Proteome Profiling
4.4.4.2. Non-Industry Players: Analysis by Service(s) Offered for Proteome Profiling
4.4.4.3. Non-Industry Players: Analysis by Other Service(s) Offered for Proteome Profiling
4.3.5. Non-Industry Industry Players: Analysis by Type of Product Profiled
4.2.6. Non-Industry Players: Analysis by Type of Sample(s) Used
4.3.7. Non-Industry Players: Analysis by Type of Application
- COMPANY PROFILES: PROTEOME PROFILING SERVICE PROVIDERS IN NORTH AMERICA
5.1. Chapter Overview
5.2. Bioproximity
5.2.1. Company Overview
5.2.2. Proteome Profiling-related Service Offerings
5.2.3. Proteome Profiling Technology
5.2.4. Recent Developments and Future Outlook
5.3. Cell Signaling Technology
5.3.1. Company Overview
5.3.2. Proteome Profiling-related Service Offerings
5.3.3. Proteome Profiling Technology
5.3.4. Recent Developments and Future Outlook
5.4. Creative Biolabs
5.4.1. Company Overview
5.4.2. Proteome Profiling-related Service Offerings
5.4.3. Proteome Profiling Technology
5.4.4. Recent Developments and Future Outlook
5.5. Creative Proteomics
5.5.1. Company Overview
5.5.2. Proteome Profiling-related Service Offerings
5.5.3. Proteome Profiling Technology
5.5.4. Recent Developments and Future Outlook
5.6. Poochon Scientific
5.6.1. Company Overview
5.6.2. Proteome Profiling-related Service Offerings
5.6.3. Proteome Profiling Technology
5.6.4. Recent Developments and Future Outlook
- COMPANY PROFILES: PROTEOME PROFILING SERVICE PROVIDERS IN EUROPE
6.1. Chapter Overview
6.2. Biognosys
6.2.1. Company Overview
6.2.2. Proteome Profiling-related Service Offerings
6.2.3. Proteome Profiling Technology
6.2.4. Recent Developments and Future Outlook
6.3. NMI TT Pharmaservices
6.3.1. Company Overview
6.3.2. Proteome Profiling-related Service Offerings
6.3.3. Proteome Profiling Technology
6.3.4. Recent Developments and Future Outlook
6.4. Proteome Factory
6.4.1. Company Overview
6.4.2. Proteome Profiling-related Service Offerings
6.4.3. Proteome Profiling Technology
6.4.4. Recent Developments and Future Outlook
6.5. Sciomics
6.5.1. Company Overview
6.5.2. Proteome Profiling-related Service Offerings
6.5.3. Proteome Profiling Technology
6.5.4. Recent Developments and Future Outlook
6.6. tebu-bio
6.6.1. Company Overview
6.6.2. Proteome Profiling-related Service Offerings
6.6.3. Proteome Profiling Technology
6.6.4. Recent Developments and Future Outlook
- COMPANY PROFILES: PROTEOME PROFILING SERVICE PROVIDERS IN ASIA PACIFIC AND REST OF THE WORLD
7.1. Chapter Overview
7.2. BGI
7.2.1. Company Overview
7.2.2. Proteome Profiling-related Service Offerings
7.2.3. Proteome Profiling Technology
7.2.4. Recent Developments and Future Outlook
7.3. Cytomics
7.3.1. Company Overview
7.3.2. Proteome Profiling-related Service Offerings
7.3.3. Proteome Profiling Technology
7.3.4. Recent Developments and Future Outlook
7.4. i-DNA Bioechnology
7.4.1. Company Overview
7.4.2. Proteome Profiling-related Service Offerings
7.4.3. Proteome Profiling Technology
7.4.4. Recent Developments and Future Outlook
7.5. Proteomics International
7.5.1. Company Overview
7.5.2. Proteome Profiling-related Service Offerings
7.5.3. Proteome Profiling Technology
7.5.4. Recent Developments and Future Outlook
7.6. VProteomics
7.6.1. Company Overview
7.6.2. Proteome Profiling-related Service Offerings
7.6.3. Proteome Profiling Technology
7.6.4. Recent Developments and Future Outlook
- COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. Competitiveness Analysis: Industry Players
8.4.1. Competitiveness Analysis: Industry Players based in North America
8.4.2. Competitiveness Analysis: Industry Players based in Europe
8.4.3. Competitiveness Analysis: Industry Players based in Asia Pacific and Rest of the World
8.5. Competitiveness Analysis: Non-Industry Players
8.5.1. Competitiveness Analysis: Non-Industry Players based in North America
8.5.2. Competitiveness Analysis: Non-Industry Players in Europe
8.5.3. Competitiveness Analysis: Non-Industry Players based in Asia Pacific and Rest of the World
- PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Proteome Profiling Services Providers: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Service Mentioned in the Agreement
9.3.5. Analysis by Type of Application Mentioned in the Agreement
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Geographical Analysis
9.3.7.1. Region-wise Distribution
9.3.7.2. Country-wise Distribution
- COST PRICE ANALYSIS
10.1. Chapter Overview
10.2. Factors Contributing to the High Price of Proteome Profiling
10.3. Price of Proteome Profiling
10.3.1. Pricing Based on Number of Proteins / Samples Processed
10.3.2. Pricing Based on Proteome Profiling Steps
10.3.3. Pricing Based on Sample Type
- SWOT ANALYSIS
11.1. Chapter Overview
11.2. Strengths
11.3. Weaknesses
11.4. Opportunities
11.5. Threats
11.6. Concluding Remarks
- MARKET SIZING AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Forecast Methodology and Assumptions
12.3. Overall Proteome Profiling Services Market, 2020-2030
12.3.1. Proteome Profiling Services Market, 2020-2030: Distribution by Type of Application
12.3.2. Proteome Profiling Services Market, 2020-2030: Distribution by Type of Sponsor
12.3.3. Proteome Profiling Services Market, 2020-2030: Geographical Distribution
12.3.4. Proteome Profiling Services Market in North America, 2020-2030
12.3.5. Proteome Profiling Services Market in Europe, 2020-2030
12.3.6. Proteome Profiling Services Market in Asia Pacific, 2020-2030
12.3.7. Proteome Profiling Services Market in Rest of the World, 2020-2030
- IMPACT OF THE COVID-19 PANDEMIC ON PROTEOME PROFILING SERVICES MARKET
13.1. Chapter Overview
13.2. Current Opinions and Recuperative Initiatives of Key Players
13.3. Impact on Future Market Opportunity for Proteome Profiling Services Market
- CONCLUDING REMARKS
- EXECUTIVE INSIGHTS
- APPENDIX 1: TABULATED DATA
- APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
Therefore, the use of technology can save time and money, while providing a far better understanding of the relationships between different formulations and processes parameters.Key Drivers, Restraints, and Opportunities of AI in Pharma and Biotech MarketAdoption of artificial intelligence (AI) in the drug discovery market in developing regions such as APAC is increasing, thanks to the expansion of pharmaceutical industries by collaborating with other industries and rise in demand to reduce drug discovery time.
Furthermore, the expansion of biotechnology industries is estimated to offer significant opportunities for the market.An estimated 50% of U.S. citizens are affected by at least one chronic condition; consequently, the pharmaceutical segment of the healthcare industry is projected to be positively impacted by the expected trend of AI adoption.All top 10 so-called giant pharma companies (namely Novartis, Roche, Pfizer, Merck, AstraZeneca, GlaxoSmithKline, Sanofi, Abbvie, Bristol-Myers Squibb, and Johnson & Johnson) have either expressly collaborated with or acquired AI technologies to take advantage of the opportunities AI brings to the table.
Industry leaders are presently focused on the development of more efficient methods, and machine learning is emerging as a possible solution.The current machine learning initiatives of the top five pharmaceutical and biotechnology companies reveal trends within the following areas:Digital coaching solutions – Utilization of web-based technologies to simulate one-on-one coaching sessions so that all patients can have the benefit of a uniquely devised medication program.For instance: Johnson & Johnson’s Patient Athlete programPersonalized medicine – Personalized medicine, also called precision medicine, maybe a medical model that separates people into different groups—with medical decisions, practices, interventions, and/or products being tailored to the individual patient supported their predicted response or risk of disease.For instance.
Unlike other applications within healthcare facilities, drug discovery seems to own a clearer path to adoption.Recently, robots became more collaborative with humans and are more easily trained by moving them through the desired task.
Over time, it seems likely that an equivalent improvement in intelligence that we have seen in other areas of AI would be incorporated into physical robots.Surgical robots initially approved in the U.S. in 2000, provided ‘superpowers’ to surgeons, improving their ability to examine, create precise and minimally invasive incisions, and stitch wounds.
Common surgical procedures using robotic surgery include gynecologic surgery, prostate surgery, and head and neck surgery.Pre Book Ai In Pharma And Biotech Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=79399=S North America to Capture Major Share of Global Market of AI in Pharma & BiotechNorth America is expected to account for a major share of the global market of AI in Pharma and Biotech due to the high prevalence of chronic diseases among the population.
Softcon Systems brings you automation solutions specific to the pharmaceutical industry – we will work with you to develop and implement ideal solutions specific to your requirements.
Automation at every point of the value chain will enable the pharma companies to get pharmaceuticals from the lab to the patient more quickly.We design systems that help pharmaceutical and biotech companies to achieve operational excellence, reduce time to market and meet all industry standards and regulations.
